Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

- 1-16. (Cancelled)
- 17. (New) A method for preparing a composite product comprising a step in which an active substance in powder form undergoes co-grinding with a carrier comprising N-vinyl-2-pyrrolidone/vinyl acetate copolymer in powder form.
- 18. (New) The method according to claim 17, in which the carrier is N-vinyl-2-pyrrolidone/vinyl acetate.
- 19. (New) The method according to claim 17, in which the co-grinding step takes place in dry conditions.
- 20. (New) The method according to claim 17, in which the active substance is chosen among non steroidal anti-inflammatory agents.
- 21. (New) The method according to claim 17, in which the active substance is chosen among anti-hypertensives.
- 22. (New) The method according to claim 17, in which the active substance is chosen among hepato-biliary agents.
- 23. (New) The method according to claim 17, in which the active substance is chosen among substances that are scarcely soluble in water environment.
- 24. (New) The method according to claim 23, in which the active substance is chosen among scarcely water soluble substances having a low dissolution speed.
- 25. (New) The method according to claim 17, in which the active substance is chosen among: anti-inflammatory agents, analgesics, relaxants, anti-microbic agents,

antiseptics, acid pump inhibitors, H₂ antagonists, anti-emetics and anti-nausea, biliary acids, oral hypoglycemizers, diuretics, anti-hypertensives, sulfonamides, ace-inhibitors, hypolipemizers, anti-mycotic agents, antihistamines, hormones, quinolone derivates, antibacterial agents, beta-lactame and fluoroquinolone antibiotics, antiviral agents, antineoplastic agents, immuno-modulators and immuno-suppressors, anti-gout agents, anesthetics, analgesics, antipyretics, 5HT₁ agonists, anti-Parkinson agents, antipyreticagents, tranquillizers, antidepressants, anti-parasitic agents, non-cortisone anti-allergic agents, anti-asthmatic agents, anti-glaucoma agents, inhibitors of carbonic anhydrase or beta-blockers.

- 26. (New) The method according to claim 25, in which the active substance is chosen among: paracetamol, nifedipine, piroxicam, ibuprofen, sulindac, diclofenac, alclofenac, ketorolac, indomethacine, naproxen, fenoprofen, flurbiprofen, ketoprofen, cimetidine, ranitidine, mesalazine, ursodeoxycholic acid, mefenamic acid, sinvastatin, megestrol acetate, lorazepam, diazepam, cyclosporin, ubiquinone, tolbutamide, ketanserine, furosemide, nicergoline, losartan, econazole, miconazole, taxol, progesterone, prednisolone, beclometasone, nalidixic acid, finasteride, ciprofloxacine, ofloxacine, lomefloxacine, methotrexate, etoposide, daunorubicine, tamoxifen, allopurinol, clodronic acid, sumatriptan, carbamazepine, clorpromazine, clozapine, sulpiride, buspirone, fluoxetine, citalopram, caffeine, metronidazole, acetazolamide.
- 27. (New) The method according to claim 17, in which the active substance and N-vinyl-2-pyrrolidone/vinyl acetate copolymer are present in a weight ratio between 1:200 and 10:1.
- 28. (New) The method according to claim 27, in which the active substance and N-vinyl-2-pyrrolidone/vinyl acetate copolymer are present in a weight ratio between 1:100 and 5:1.
- 29. (New) The method according to claim 17, in which the active substance and N-vinyl-2-pyrrolidone/vinyl acetate copolymer are premixed in powder mixer.
- 30. (New) The method according to claim 17, in which the mixture comprising the active substance and N-vinyl-2-pyrrolidone/vinyl acetate copolymer is introduced into the grinding mill without premixing.

- 31. (New) The method according to claim 17, in which powder granulometry of both the active substance and N-vinyl-2-pyrrolidone/vinyl acetate copolymer is within a range between 0.01 and 1,000 microns.
- 32. (New) The method according to claim 17, in which co-grinding is carried out at low or high energy for times varying from 0.1 to 48 hours.
- 33. (New) The method according to claim 32, in which co-grinding is carried out at low or high energy for times between 0.5 to 8 hours.